Ciprofloxacin and Dexamethasone

Ciprofloxacin and Dexamethasone
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ciprofloxacin and Dexamethasone is an anti-infective/anti inflammatory that is FDA approved for the treatment of acute otitis externa, acute otitis media associated with typanostomy tube. Common adverse reactions include discomfort of ear, otalgia, pruritus of skin and ear.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Acute Otitis Externa

• CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in acute otitis externa in pediatric, adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.

• Dosing information:

• Otitis externa, acute: 4 drops into the affected ear twice a day for 7 days.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ciprofloxacin and Dexamethasone in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ciprofloxacin and Dexamethasone in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

• CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:

• Acute Otitis Media in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.
  • Acute Otitis Externa in pediatric (age 6 months and older) patients due to Staphylococcus aureus and Pseudomonas aeruginosa.

Acute Otitis Media with typanostomy tube

• Dosing information:

• Acute Otitis Media in pediatric patients with tympanostomy tubes: The recommended dosage regimen for the treatment of acute otitis media in pediatric patients (age 6 months and older) through tympanostomy tubes is: Four drops (0.14 mL, 0.42 mg ciprofloxacin, 0.14 mg dexamethasone) instilled into the affected ear twice daily for seven days.

Acute Otitis Externa

• Dosing information:

• The recommended dosage regimen for the treatment of acute otitis externa is: For patients (age 6 months and older): Four drops (0.14 mL, 0.42 mg ciprofloxacin, 0.14 mg dexamethasone) instilled into the affected ear twice daily for seven days.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ciprofloxacin and Dexamethasone in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ciprofloxacin and Dexamethasone in pediatric patients.

Contraindications

CIPRODEX® Otic is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. Use of this product is contraindicated in viral infections of the external canal including herpes simplex infections.

Warnings

FOR OTIC USE ONLY

(This product is not approved for ophthalmic use.)

NOT FOR INJECTION

• CIPRODEX® Otic should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Serious acute hypersensitivity reactions may require immediate emergency treatment.

Adverse Reactions

Clinical Trials Experience

• In Phases II and III clinical trials, a total of 937 patients were treated with CIPRODEX® Otic. This included 400 patients with acute otitis media with tympanostomy tubes and 537 patients with acute otitis externa. The reported treatment-related adverse events are listed below:

Acute Otitis Media in pediatric patients with tympanostomy tubes

• The following treatment-related adverse events occurred in 0.5% or more of the patients with non-intact tympanic membranes.

• The following treatment-related adverse events were each reported in a single patient: tympanostomy tube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizziness; and erythema.

Acute Otitis Externa

• The following treatment-related adverse events occurred in 0.4% or more of the patients with intact tympanic membranes.

• The following treatment-related adverse events were each reported in a single patient: ear discomfort; decreased hearing; and ear disorder (tingling).

Postmarketing Experience

There is limited information regarding Ciprofloxacin and Dexamethasone Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Ciprofloxacin and Dexamethasone Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Ciprofloxacin and Dexamethasone in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ciprofloxacin and Dexamethasone in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ciprofloxacin and Dexamethasone during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in geriatric settings.

Gender

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ciprofloxacin and Dexamethasone in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ciprofloxacin and Dexamethasone in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Ciprofloxacin and Dexamethasone Administration in the drug label.

Monitoring

There is limited information regarding Ciprofloxacin and Dexamethasone Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Ciprofloxacin and Dexamethasone and IV administrations.

Overdosage

There is limited information regarding Ciprofloxacin and Dexamethasone overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Ciprofloxacin and Dexamethasone Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ciprofloxacin and Dexamethasone Mechanism of Action in the drug label.

Structure

• CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension contains the synthetic broad-spectrum antibacterial agent, ciprofloxacin hydrochloride, combined with the anti-inflammatory corticosteroid, dexamethasone, in a sterile, preserved suspension for otic use. Each mL of CIPRODEX® Otic contains ciprofloxacin hydrochloride (equivalent to 3 mg ciprofloxacin base), 1 mg dexamethasone, and 0.1 mg benzalkonium chloride as a preservative. The inactive ingredients are boric acid, sodium chloride, hydroxyethyl cellulose, tyloxapol, acetic acid, sodium acetate, edetate disodium, and purified water. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.

• Ciprofloxacin, a fluoroquinolone is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-qui nolinecarboxylic acid. The empirical formula is C17H18FN3O3·HCl·H2O and the structural formula is:

Dexamethasone,9-fluoro-11(beta),17,21-trihydroxy-16(alpha)-methylpregna-1,4-di ene-3,20-dione, is an anti-inflammatory corticosteroid. The empirical formula is C22H29FO5 and the structural formula is:

Pharmacodynamics

There is limited information regarding Ciprofloxacin and Dexamethasone Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Ciprofloxacin and Dexamethasone Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Ciprofloxacin and Dexamethasone Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Ciprofloxacin and Dexamethasone Clinical Studies in the drug label.

How Supplied

• CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension is supplied as follows: 7.5 mL fill in a DROP-TAINER® system. The DROP-TAINER® system consists

• Of a natural polyethylene bottle and natural plug, with a white polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.

• NDC 0065-8533-02, 7.5 mL fill

Storage

Store at controlled room temperature, 15°C to 30°C (59°F to 86°F). Avoid freezing. Protect from light.

Images

Drug Images

{{#ask: Page Name::Ciprofloxacin and Dexamethasone |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ciprofloxacin and Dexamethasone |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Ciprofloxacin and Dexamethasone Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Ciprofloxacin and Dexamethasone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Ciprofloxacin and Dexamethasone Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Ciprofloxacin and Dexamethasone Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.